Inhibikase Therapeutics, Inc. (IKT) earnings
Quarterly results of Inhibikase Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Inhibikase Therapeutics, Inc. is expected to report around November 13, 2026. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Inhibikase Therapeutics, Inc. reported revenue of $0 and a net loss of $19.6M.
Diluted earnings per share were -$0.11.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $0 | - | -$19.6M | -$0.11 |
| Q1 FY2026 | $0 | - | -$16.4M | -$0.10 |
| Q4 FY2025 | - | - | -$12.7M | - |
| Q3 FY2025 | $0 | - | -$11.9M | -$0.13 |
| Q2 FY2025 | $0 | - | -$9.9M | -$0.11 |
| Q1 FY2025 | $0 | - | -$13.7M | -$0.15 |
| Q4 FY2024 | $0 | - | -$12.1M | - |
| Q3 FY2024 | $0 | - | -$5.8M | -$0.65 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
When is Inhibikase Therapeutics, Inc.'s next earnings date?
Inhibikase Therapeutics, Inc. is expected to report around November 13, 2026. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.
What were Inhibikase Therapeutics, Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Inhibikase Therapeutics, Inc. reported revenue of $0 and a net loss of $19.6M. The figures come from its filing with the SEC.
Get an email when IKT reports
Follow IKT and we email you its next results the day they are filed, with the numbers explained.